AbbVie's Pain Is Sanofi's and Regeneron's Gain

·2 min read

There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting